Related Experiment Video
Updated: Feb 5, 2026

04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.9K
Interstitial Cystitis: An Update on the Disease Process and Treatment
Journal of Pain & Palliative Care Pharmacotherapy
|September 14, 2018
Summary
Interstitial cystitis (IC), a chronic bladder pain disorder, is frequently misdiagnosed due to complex causes. Understanding its pathophysiology and symptoms aids healthcare providers in accurate diagnosis and effective management of IC.
Area of Science:
- Urology
- Pain Medicine
- Internal Medicine
Background:
- Interstitial cystitis (IC) is a chronic bladder pain condition.
- It is often underdiagnosed and mistreated, leading to increased patient suffering.
- Current diagnostic challenges arise from multiple proposed etiologies and pathophysiological mechanisms.
Purpose of the Study:
- To review the pathophysiology, pain pathways, and symptoms of IC.
- To improve healthcare providers' understanding of IC for better diagnosis and management.
- To provide a framework for identifying patients with IC based on clinical presentation and risk factors.
Main Methods:
- Literature review of existing research on IC pathophysiology and diagnosis.
- Analysis of proposed etiological factors including GAG layer breakdown, urothelial permeability, uroinflammation, and neural changes.
- Discussion of clinical presentation and risk factors for IC.
Main Results:
- IC pathophysiology involves multiple factors, including bladder lining integrity and nerve signaling.
- Accurate diagnosis is hindered by a lack of definitive biomarkers and overlapping symptoms with other conditions.
- Early and correct diagnosis is crucial for effective symptom management and improved quality of life.
Conclusions:
- A comprehensive understanding of IC's complex pathophysiology is essential for accurate diagnosis.
- Integrating clinical evaluation with risk factor assessment can improve diagnostic accuracy.
- Improved diagnostic and management strategies for IC are needed to reduce patient burden.
Related Concept Videos
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
956
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
956
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
510
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
510
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
542
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
542
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
558
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
558
Parallel Processing
730
The brain processes sensory information rapidly due to parallel processing, which involves sending data across multiple neural pathways at the same time. This method allows the brain to manage various sensory qualities, such as shapes, colors, movements, and locations, all concurrently. For instance, when observing a forest landscape, the brain simultaneously processes the movement of leaves, the shapes of trees, the depth between them, and the various shades of green. This enables a quick and...
730

